|
Luye Pharma Group Ltd. (2186.HK) DCF Valuation |
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Luye Pharma Group Ltd. (2186.HK) Bundle
Explore the financial future of Luye Pharma Group Ltd. (2186HK) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to determine the intrinsic value of Luye Pharma Group Ltd. (2186HK) and inform your investment decisions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,825.2 | 5,947.1 | 5,582.7 | 6,421.6 | 6,594.9 | 7,155.3 | 7,763.4 | 8,423.1 | 9,138.9 | 9,915.6 |
| Revenue Growth, % | 0 | -12.87 | -6.13 | 15.03 | 2.7 | 8.5 | 8.5 | 8.5 | 8.5 | 8.5 |
| EBITDA | 2,560.5 | 2,015.1 | 973.6 | 1,946.2 | 2,230.2 | 2,189.0 | 2,375.0 | 2,576.8 | 2,795.8 | 3,033.4 |
| EBITDA, % | 37.51 | 33.88 | 17.44 | 30.31 | 33.82 | 30.59 | 30.59 | 30.59 | 30.59 | 30.59 |
| Depreciation | 474.5 | 548.5 | 624.8 | 720.7 | 753.5 | 715.7 | 776.6 | 842.6 | 914.2 | 991.8 |
| Depreciation, % | 6.95 | 9.22 | 11.19 | 11.22 | 11.43 | 10 | 10 | 10 | 10 | 10 |
| EBIT | 2,085.9 | 1,466.7 | 348.8 | 1,225.5 | 1,476.7 | 1,473.2 | 1,598.4 | 1,734.3 | 1,881.7 | 2,041.6 |
| EBIT, % | 30.56 | 24.66 | 6.25 | 19.08 | 22.39 | 20.59 | 20.59 | 20.59 | 20.59 | 20.59 |
| Total Cash | 5,569.7 | 5,803.9 | 5,915.6 | 5,952.0 | 6,555.6 | 6,744.5 | 7,317.6 | 7,939.4 | 8,614.1 | 9,346.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,946.4 | 1,667.3 | 1,894.9 | 1,914.9 | 2,528.1 | 2,270.4 | 2,463.3 | 2,672.7 | 2,899.8 | 3,146.2 |
| Account Receivables, % | 28.52 | 28.04 | 33.94 | 29.82 | 38.33 | 31.73 | 31.73 | 31.73 | 31.73 | 31.73 |
| Inventories | 659.8 | 657.3 | 801.2 | 829.8 | 888.8 | 879.7 | 954.4 | 1,035.6 | 1,123.6 | 1,219.0 |
| Inventories, % | 9.67 | 11.05 | 14.35 | 12.92 | 13.48 | 12.29 | 12.29 | 12.29 | 12.29 | 12.29 |
| Accounts Payable | 366.1 | 521.0 | 612.9 | 601.1 | 823.6 | 671.9 | 729.0 | 791.0 | 858.2 | 931.1 |
| Accounts Payable, % | 5.36 | 8.76 | 10.98 | 9.36 | 12.49 | 9.39 | 9.39 | 9.39 | 9.39 | 9.39 |
| Capital Expenditure | -3,460.1 | -1,631.7 | -1,655.0 | -1,249.2 | -1,251.0 | -2,092.2 | -2,270.0 | -2,462.9 | -2,672.2 | -2,899.3 |
| Capital Expenditure, % | -50.7 | -27.44 | -29.64 | -19.45 | -18.97 | -29.24 | -29.24 | -29.24 | -29.24 | -29.24 |
| Tax Rate, % | 23.92 | 23.92 | 23.92 | 23.92 | 23.92 | 23.92 | 23.92 | 23.92 | 23.92 | 23.92 |
| EBITAT | 1,729.1 | 1,099.9 | 677.3 | 1,106.6 | 1,123.4 | 1,250.1 | 1,356.3 | 1,471.6 | 1,596.6 | 1,732.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -3,496.6 | 453.1 | -632.4 | 517.8 | 176.2 | -11.3 | -347.7 | -377.3 | -409.3 | -444.1 |
| WACC, % | 7.41 | 7.09 | 8.1 | 7.71 | 7.13 | 7.49 | 7.49 | 7.49 | 7.49 | 7.49 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,231.4 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -462 | |||||||||
| Terminal Value | -13,239 | |||||||||
| Present Terminal Value | -9,226 | |||||||||
| Enterprise Value | -10,458 | |||||||||
| Net Debt | 5,566 | |||||||||
| Equity Value | -16,024 | |||||||||
| Diluted Shares Outstanding, MM | 3,728 | |||||||||
| Equity Value Per Share | -4.30 |
Benefits You Will Receive
- Flexible Forecast Inputs: Effortlessly adjust parameters (growth %, margins, WACC) to explore various scenarios.
- Comprehensive Financial Data: Luye Pharma Group Ltd. (2186HK) financial information pre-loaded to enhance your analysis.
- Instant DCF Outputs: The model automatically computes Net Present Value (NPV) and intrinsic value.
- Tailored and Professional: A sleek Excel model designed to meet your valuation requirements.
- Crafted for Analysts and Investors: Perfect for evaluating forecasts, assessing strategies, and optimizing your time.
Key Features
- 🔍 Real-Life 2186HK Financials: Pre-filled historical and projected data for Luye Pharma Group Ltd.
- ✏️ Fully Customizable Inputs: Tailor critical parameters (yellow cells) such as WACC, growth %, and tax rates to your needs.
- 📊 Professional DCF Valuation: Utilize built-in formulas to determine Luye Pharma’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Immediately visualize Luye Pharma’s valuation after making any adjustments.
- Scenario Analysis: Evaluate and compare different outcomes based on various financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template featuring Luye Pharma Group Ltd. (2186HK) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the key metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see recalculated results, including Luye Pharma Group Ltd.'s (2186HK) intrinsic value.
- Step 5: Use the outputs to make informed investment decisions or generate detailed reports.
Why Choose Luye Pharma Group Ltd. (2186HK) Calculator?
- Accuracy: Leverages real Luye Pharma financial data for precise calculations.
- Flexibility: Tailored for users to easily experiment with and adjust inputs.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected by CFOs.
- User-Friendly: Intuitive interface makes it accessible for all users, regardless of financial modeling experience.
Who Should Consider This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for assessing portfolios related to Luye Pharma Group Ltd. (2186HK).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Equip clients with precise valuation insights on Luye Pharma Group Ltd. (2186HK).
- Students and Educators: Utilize real market data to enhance learning and practice in financial modeling.
- Healthcare Enthusiasts: Gain insights into the valuation process of pharmaceutical companies like Luye Pharma Group Ltd. (2186HK).
Contents of the Template
- Preloaded LUYE Data: Historical and projected financial information, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-quality spreadsheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Cells highlighted in yellow for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial reports for in-depth analysis.
- Key Ratios: Metrics on profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.